These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8624760)

  • 1. Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group.
    Raboud JM; Montaner JS; Thorne A; Singer J; Schechter MT
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):46-55. PubMed ID: 8624760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
    Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    ;
    AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
    Goldman AI; Carlin BP; Crane LR; Launer C; Korvick JA; Deyton L; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):161-9. PubMed ID: 8556398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.
    Montaner JS; Gill J; Singer J; Raboud J; Arseneau R; McLean BD; Schechter MT; Ruedy J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):153-7. PubMed ID: 8680886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
    Kazempour K; Kammerman LA; Farr SS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S97-106. PubMed ID: 7552521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.